{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:45:51Z","timestamp":1792107951077,"version":"4.4.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"DOI":"10.1007\/s11912-026-01843-x","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:56:07Z","timestamp":1792104967000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinically Significant Portal Hypertension in Hepatocellular Carcinoma: Non-Invasive Assessment Across the Continuum"],"prefix":"10.1007","volume":"28","author":[{"given":"Pengcheng","family":"Ji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulu","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7464-260X","authenticated-orcid":false,"given":"Zhengguo","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,15]]},"reference":[{"key":"1843_CR1","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1053\/j.gastro.2007.05.024","volume":"133","author":"C Ripoll","year":"2007","unstructured":"Ripoll C, Groszmann R, Garcia-Tsao G, Grace N, Burroughs A, Planas R, et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology. 2007;133:481\u20138. https:\/\/doi.org\/10.1053\/j.gastro.2007.05.024.","journal-title":"Gastroenterology"},{"key":"1843_CR2","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","volume":"76","author":"R de Franchis","year":"2022","unstructured":"de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C. Baveno VII - Renewing consensus in portal hypertension. J Hepatol. 2022;76:959\u201374. https:\/\/doi.org\/10.1016\/j.jhep.2021.12.022.","journal-title":"J Hepatol"},{"key":"1843_CR3","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/s41575-026-01209-5","volume":"23","author":"M Allaire","year":"2026","unstructured":"Allaire M, Taddei T, Thabut D, Garcia-Tsao G. Cirrhosis, portal hypertension and hepatocellular carcinoma: a stage-based approach. Nat Rev Gastroenterol Hepatol. 2026;23:628\u201340. https:\/\/doi.org\/10.1038\/s41575-026-01209-5.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1843_CR4","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/nrgastro.2009.149","volume":"6","author":"J Bosch","year":"2009","unstructured":"Bosch J, Abraldes JG, Berzigotti A, Garc\u00eda-Pagan JC. The clinical use of HVPG measurements in chronic liver disease. Nat Rev Gastroenterol Hepatol. 2009;6:573\u201382. https:\/\/doi.org\/10.1038\/nrgastro.2009.149.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1843_CR5","doi-asserted-by":"publisher","first-page":"100316","DOI":"10.1016\/j.jhepr.2021.100316","volume":"3","author":"Y Iwakiri","year":"2021","unstructured":"Iwakiri Y, Trebicka J. Portal hypertension in cirrhosis: pathophysiological mechanisms and therapy. JHEP Rep. 2021;3:100316. https:\/\/doi.org\/10.1016\/j.jhepr.2021.100316.","journal-title":"JHEP Rep"},{"key":"1843_CR6","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1097\/HEP.0000000000000291","volume":"79","author":"M Allaire","year":"2024","unstructured":"Allaire M, Thabut D. Portal hypertension and variceal bleeding in patients with liver cancer: evidence gaps for prevention and management. Hepatology. 2024;79:213\u201323. https:\/\/doi.org\/10.1097\/HEP.0000000000000291.","journal-title":"Hepatology"},{"key":"1843_CR7","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.jhep.2015.05.022","volume":"63","author":"R de Franchis","year":"2015","unstructured":"de Franchis R. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63:743\u201352. https:\/\/doi.org\/10.1016\/j.jhep.2015.05.022.","journal-title":"J Hepatol"},{"key":"1843_CR8","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/S2468-1253(24)00234-6","volume":"9","author":"M Jachs","year":"2024","unstructured":"Jachs M, Odriozola A, Turon F, Moga L, T\u00e9llez L, Fischer P, et al. Spleen stiffness measurement by vibration-controlled transient elastography at 100 Hz for non-invasive predicted diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease: a modelling study. Lancet Gastroenterol Hepatol. 2024;9:1111\u201320. https:\/\/doi.org\/10.1016\/S2468-1253(24)00234-6.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1843_CR9","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/S2468-1253(23)00150-4","volume":"8","author":"E Dajti","year":"2023","unstructured":"Dajti E, Ravaioli F, Zykus R, Rautou PE, Elkrief L, Grgurevic I, et al. Accuracy of spleen stiffness measurement for the diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease: a systematic review and individual patient data meta-analysis. Lancet Gastroenterol Hepatol. 2023;8:816\u201328. https:\/\/doi.org\/10.1016\/S2468-1253(23)00150-4.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1843_CR10","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1097\/HEP.0000000000001183","volume":"82","author":"P Vutien","year":"2025","unstructured":"Vutien P, Barnard Giustini A, Kim NJ, Moon AM, Hsu CN, Mezzacappa C, et al. Validation and expansion of Baveno VII criteria for cACLD and CSPH based on liver stiffness and platelet count: correlation with risk of hepatic decompensation and death. Hepatology. 2025;82:422\u201337. https:\/\/doi.org\/10.1097\/HEP.0000000000001183.","journal-title":"Hepatology"},{"key":"1843_CR11","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1111\/jgh.16218","volume":"38","author":"CW Wu","year":"2023","unstructured":"Wu CW, Wong GL, Wong VW, Yam TF, Yip TC, Wong AC, et al. Baveno VII criteria identify varices needing treatment in patients with hepatocellular carcinoma of different Barcelona Clinic Liver Cancer stages. J Gastroenterol Hepatol. 2023;38:1381\u20138. https:\/\/doi.org\/10.1111\/jgh.16218.","journal-title":"J Gastroenterol Hepatol"},{"key":"1843_CR12","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/apt.17599","volume":"58","author":"M Allaire","year":"2023","unstructured":"Allaire M, Campion B, Demory A, Larrey E, Wagner M, Rudler M, et al. Baveno VI and VII criteria are not suitable for screening for large varices or clinically significant portal hypertension in patients with hepatocellular carcinoma. Aliment Pharmacol Ther. 2023;58:346\u201356. https:\/\/doi.org\/10.1111\/apt.17599.","journal-title":"Aliment Pharmacol Ther"},{"key":"1843_CR13","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/jgh.16415","volume":"39","author":"M Allaire","year":"2024","unstructured":"Allaire M, Thabut D. The applicability of Baveno criteria in the setting of hepatocellular carcinoma remains a controversy. J Gastroenterol Hepatol. 2024;39:211. https:\/\/doi.org\/10.1111\/jgh.16415.","journal-title":"J Gastroenterol Hepatol"},{"key":"1843_CR14","doi-asserted-by":"publisher","first-page":"e0542","DOI":"10.1097\/HC9.0000000000000542","volume":"8","author":"A Ullah","year":"2024","unstructured":"Ullah A, Choudhary UIJ, Khan NA, Shah SB. Baveno VII for HCC: are we there yet? Hepatol Commun. 2024;8:e0542. https:\/\/doi.org\/10.1097\/HC9.0000000000000542.","journal-title":"Hepatol Commun"},{"key":"1843_CR15","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1111\/apt.17626","volume":"58","author":"C Moctezuma-Velazquez","year":"2023","unstructured":"Moctezuma-Velazquez C, Abraldes JG. Editorial: the use of Baveno VI and VII criteria in patients with hepatocellular carcinoma. Aliment Pharmacol Ther. 2023;58:478\u20139. https:\/\/doi.org\/10.1111\/apt.17626.","journal-title":"Aliment Pharmacol Ther"},{"key":"1843_CR16","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.jhep.2022.11.019","volume":"78","author":"D Thabut","year":"2023","unstructured":"Thabut D, Kudo M. Treatment of portal hypertension in patients with HCC in the era of Baveno VII. J Hepatol. 2023;78:658\u201362. https:\/\/doi.org\/10.1016\/j.jhep.2022.11.019.","journal-title":"J Hepatol"},{"key":"1843_CR17","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1111\/apt.17850","volume":"59","author":"X Cheng","year":"2024","unstructured":"Cheng X, Tang Y, He Q, Song J, Wang K, Li H, et al. Spleen-dedicated stiffness measurement performed well to rule out high-risk varices in HBV-related hepatocellular carcinoma: screening for high-risk varices in HCC. Aliment Pharmacol Ther. 2024;59:680\u201391. https:\/\/doi.org\/10.1111\/apt.17850.","journal-title":"Aliment Pharmacol Ther"},{"key":"1843_CR18","doi-asserted-by":"publisher","unstructured":"de Paiva Guimar\u00e3es Barreiro T, Golfi JE, Penachim TJ, Silva Pacetti PH, Perales S, Boin I et al. Imaging of spontaneous portosystemic shunts in portal hypertension: clinical significance and structured reporting. Abdom Radiol. 2026. https:\/\/doi.org\/10.1007\/s00261-026-05618-7","DOI":"10.1007\/s00261-026-05618-7"},{"key":"1843_CR19","doi-asserted-by":"publisher","first-page":"110010","DOI":"10.1016\/j.ejrad.2021.110010","volume":"147","author":"M Renzulli","year":"2022","unstructured":"Renzulli M, Dajti E, Ierardi AM, Brandi N, Berzigotti A, Milandri M, et al. Validation of a standardized CT protocol for the evaluation of varices and porto-systemic shunts in cirrhotic patients. Eur J Radiol. 2022;147:110010. https:\/\/doi.org\/10.1016\/j.ejrad.2021.110010.","journal-title":"Eur J Radiol"},{"key":"1843_CR20","doi-asserted-by":"publisher","first-page":"e70368","DOI":"10.1111\/liv.70368","volume":"45","author":"E Ozkaya","year":"2025","unstructured":"Ozkaya E, Bane O, Bhuiyan E, Geahchan A, Altinmakas E, Hectors SJ, et al. Multiparametric MRI for diagnosing clinically significant portal hypertension and predicting liver decompensation. Liver Int. 2025;45:e70368. https:\/\/doi.org\/10.1111\/liv.70368.","journal-title":"Liver Int"},{"key":"1843_CR21","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1016\/j.cgh.2020.03.034","volume":"18","author":"Y Liu","year":"2020","unstructured":"Liu Y, Ning Z, \u00d6rmeci N, An W, Yu Q, Han K, et al. Deep convolutional neural network-aided detection of portal hypertension in patients with cirrhosis. Clin Gastroenterol Hepatol. 2020;18:2998\u20133007. https:\/\/doi.org\/10.1016\/j.cgh.2020.03.034.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1843_CR22","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.ebiom.2018.09.023","volume":"36","author":"F Liu","year":"2018","unstructured":"Liu F, Ning Z, Liu Y, Liu D, Tian J, Luo H, et al. Development and validation of a radiomics signature for clinically significant portal hypertension in cirrhosis (CHESS1701): a prospective multicenter study. EBioMedicine. 2018;36:151\u20138. https:\/\/doi.org\/10.1016\/j.ebiom.2018.09.023.","journal-title":"EBioMedicine"},{"key":"1843_CR23","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1016\/j.jhep.2022.03.026","volume":"76","author":"QM Anstee","year":"2022","unstructured":"Anstee QM, Castera L, Loomba R. Impact of non-invasive biomarkers on hepatology practice: past, present and future. J Hepatol. 2022;76:1362\u201378. https:\/\/doi.org\/10.1016\/j.jhep.2022.03.026.","journal-title":"J Hepatol"},{"key":"1843_CR24","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1002\/cncr.23339","volume":"112","author":"B Sangro","year":"2008","unstructured":"Sangro B, Gil-Alzugaray B, Rodriguez J, Sola I, Martinez-Cuesta A, Viudez A, et al. Liver disease induced by radioembolization of liver tumors: description and possible risk factors. Cancer. 2008;112:1538\u201346. https:\/\/doi.org\/10.1002\/cncr.23339.","journal-title":"Cancer"},{"issue":"3 Suppl","key":"1843_CR25","doi-asserted-by":"publisher","first-page":"S94","DOI":"10.1016\/j.ijrobp.2009.06.092","volume":"76","author":"CC Pan","year":"2010","unstructured":"Pan CC, Kavanagh BD, Dawson LA, Li XA, Das SK, Miften M, et al. Radiation-associated liver injury. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S94\u2013100. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.06.092.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1843_CR26","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1016\/S0140-6736(18)31875-0","volume":"393","author":"C Villanueva","year":"2019","unstructured":"Villanueva C, Albillos A, Genesc\u00e0 J, Garcia-Pagan JC, Calleja JL, Aracil C, et al. Beta blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2019;393:1597\u2013608. https:\/\/doi.org\/10.1016\/S0140-6736(18)31875-0.","journal-title":"Lancet"},{"key":"1843_CR27","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/hep.510300124","volume":"30","author":"R Ba\u00f1ares","year":"1999","unstructured":"Ba\u00f1ares R, Moitinho E, Piqueras B, Casado M, Garc\u00eda-Pag\u00e1n JC, de Diego A, et al. Carvedilol, a new nonselective beta-blocker with intrinsic anti-alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis. Hepatology. 1999;30:79\u201383. https:\/\/doi.org\/10.1002\/hep.510300124.","journal-title":"Hepatology"},{"key":"1843_CR28","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1111\/liv.15559","volume":"43","author":"L Turco","year":"2023","unstructured":"Turco L, Reiberger T, Vitale G, La Mura V. Carvedilol as the new non-selective beta-blocker of choice in patients with cirrhosis and portal hypertension. Liver Int. 2023;43:1183\u201394. https:\/\/doi.org\/10.1111\/liv.15559.","journal-title":"Liver Int"},{"key":"1843_CR29","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jhep.2024.12.017","volume":"83","author":"JI Fortea","year":"2025","unstructured":"Fortea JI, Alvarado-Tapias E, Simbrunner B, Ezcurra I, Hern\u00e1ndez-Gea V, Aracil C, et al. Carvedilol vs. propranolol for the prevention of decompensation and mortality in patients with compensated and decompensated cirrhosis. J Hepatol. 2025;83:70\u201380. https:\/\/doi.org\/10.1016\/j.jhep.2024.12.017.","journal-title":"J Hepatol"},{"key":"1843_CR30","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.14309\/ajg.0000000000003650","volume":"121","author":"R Khajuria","year":"2026","unstructured":"Khajuria R, Jindal A, Sharma MK, Arora V, Vyas AK, Kumar G, et al. Efficacy and safety of carvedilol in cirrhosis patients with new-onset uncomplicated ascites without high-risk esophageal varices (CARVE-AS Trial). Am J Gastroenterol. 2026;121:1372\u201381. https:\/\/doi.org\/10.14309\/ajg.0000000000003650.","journal-title":"Am J Gastroenterol"},{"key":"1843_CR31","doi-asserted-by":"publisher","first-page":"e081623","DOI":"10.1136\/bmjopen-2023-081623","volume":"14","author":"C Liu","year":"2024","unstructured":"Liu C, Zhang L, Zhang S, Li X, Wong YJ, Liang X, et al. Carvedilol to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by liver stiffness: study protocol for a randomised, double-blind, placebo-controlled, multicentre trial in China. BMJ Open. 2024;14:e081623. https:\/\/doi.org\/10.1136\/bmjopen-2023-081623.","journal-title":"BMJ Open"},{"key":"1843_CR32","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1080\/17474124.2025.2530605","volume":"19","author":"D Rojo","year":"2025","unstructured":"Rojo D, Jim\u00e9nez-Masip A, Pag\u00e8s L, Ba\u00f1ares J, Sabiote C, Mart\u00ednez-G\u00f3mez M, et al. Assessment and management of portal hypertension in patients with MASLD: advances and caveats. Expert Rev Gastroenterol Hepatol. 2025;19:903\u201317. https:\/\/doi.org\/10.1080\/17474124.2025.2530605.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"1843_CR33","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1053\/j.gastro.2023.06.013","volume":"165","author":"JJ Wattacheril","year":"2023","unstructured":"Wattacheril JJ, Abdelmalek MF, Lim JK, Sanyal AJ. AGA clinical practice update on the role of noninvasive biomarkers in the evaluation and management of nonalcoholic fatty liver disease: expert review. Gastroenterology. 2023;165:1080\u20138. https:\/\/doi.org\/10.1053\/j.gastro.2023.06.013.","journal-title":"Gastroenterology"},{"key":"1843_CR34","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1002\/hep4.1855","volume":"6","author":"T Reiberger","year":"2022","unstructured":"Reiberger T. The value of liver and spleen stiffness for evaluation of portal hypertension in compensated cirrhosis. Hepatol Commun. 2022;6:950\u201364. https:\/\/doi.org\/10.1002\/hep4.1855.","journal-title":"Hepatol Commun"},{"key":"1843_CR35","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.14309\/ajg.0000000000003741","volume":"121","author":"JH Prakash","year":"2026","unstructured":"Prakash JH, Anirvan P, Gupta S, Chouhan MI, Chaudhary M, Sahoo B, et al. Diagnostic accuracy of spleen-dedicated 100 Hz transient elastography to predict high-risk esophageal varices. Am J Gastroenterol. 2026;121:1659\u201366. https:\/\/doi.org\/10.14309\/ajg.0000000000003741.","journal-title":"Am J Gastroenterol"},{"key":"1843_CR36","doi-asserted-by":"publisher","first-page":"e70261","DOI":"10.1111\/liv.70261","volume":"45","author":"C Sebesta","year":"2025","unstructured":"Sebesta C, Jachs M, Hartl L, Schwarz M, Balcar L, Hofer BS, et al. Diagnostic and clinical implications of high spleen-to-liver stiffness ratio in MASH: a prospective, comparative study. Liver Int. 2025;45:e70261. https:\/\/doi.org\/10.1111\/liv.70261.","journal-title":"Liver Int"},{"key":"1843_CR37","doi-asserted-by":"publisher","unstructured":"Dajti E, Huber AT, Ferraioli G, Berzigotti A. Advances in imaging - Elastography. Hepatology. 2025 Apr 2. https:\/\/doi.org\/10.1097\/HEP.0000000000001342","DOI":"10.1097\/HEP.0000000000001342"},{"key":"1843_CR38","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.jhep.2013.12.015","volume":"60","author":"P Iranmanesh","year":"2014","unstructured":"Iranmanesh P, Vazquez O, Terraz S, Majno P, Spahr L, Poncet A, et al. Accurate computed tomography-based portal pressure assessment in patients with hepatocellular carcinoma. J Hepatol. 2014;60:969\u201374. https:\/\/doi.org\/10.1016\/j.jhep.2013.12.015.","journal-title":"J Hepatol"},{"key":"1843_CR39","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jhep.2015.08.025","volume":"64","author":"A Cucchetti","year":"2016","unstructured":"Cucchetti A, Cescon M, Golfieri R, Piscaglia F, Renzulli M, Neri F, et al. Hepatic venous pressure gradient in the preoperative assessment of patients with resectable hepatocellular carcinoma. J Hepatol. 2016;64:79\u201386. https:\/\/doi.org\/10.1016\/j.jhep.2015.08.025.","journal-title":"J Hepatol"},{"key":"1843_CR40","doi-asserted-by":"publisher","first-page":"100190","DOI":"10.1016\/j.jhepr.2020.100190","volume":"3","author":"D Azoulay","year":"2021","unstructured":"Azoulay D, Ramos E, Casellas-Robert M, Salloum C, Llad\u00f3 L, Nadler R, et al. Liver resection for hepatocellular carcinoma in patients with clinically significant portal hypertension. JHEP Rep. 2021;3:100190. https:\/\/doi.org\/10.1016\/j.jhepr.2020.100190.","journal-title":"JHEP Rep"},{"key":"1843_CR41","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1097\/SLA.0000000000006185","volume":"280","author":"D Aliseda","year":"2024","unstructured":"Aliseda D, Zozaya G, Mart\u00ed-Cruchaga P, Herrero I, I\u00f1arrairaegui M, Argem\u00ed J, et al. The impact of portal hypertension assessment method on the outcomes of hepatocellular carcinoma resection: a meta-analysis of matched cohort and prospective studies. Ann Surg. 2024;280:46\u201355. https:\/\/doi.org\/10.1097\/SLA.0000000000006185.","journal-title":"Ann Surg"},{"key":"1843_CR42","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1177\/2050640619840199","volume":"7","author":"B Scheiner","year":"2019","unstructured":"Scheiner B, Ulbrich G, Mandorfer M, Reiberger T, M\u00fcller C, Waneck F, et al. Short- and long-term effects of transarterial chemoembolization on portal hypertension in patients with hepatocellular carcinoma. United Eur Gastroenterol J. 2019;7:850\u20138. https:\/\/doi.org\/10.1177\/2050640619840199.","journal-title":"United Eur Gastroenterol J"},{"key":"1843_CR43","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.jhep.2025.10.019","volume":"84","author":"M Jachs","year":"2026","unstructured":"Jachs M, Th\u00f6ne P, Odriozola A, Turon F, Moga L, T\u00e9llez L, et al. Predicting hepatic decompensation using non-invasive tests in a contemporary multicentre cohort of patients with cACLD. J Hepatol. 2026;84:738\u201348. https:\/\/doi.org\/10.1016\/j.jhep.2025.10.019.","journal-title":"J Hepatol"},{"key":"1843_CR44","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894\u2013905. https:\/\/doi.org\/10.1056\/NEJMoa1915745.","journal-title":"N Engl J Med"},{"key":"1843_CR45","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1111\/apt.18526","volume":"61","author":"K Park","year":"2025","unstructured":"Park K, Lee HW, Kim E, Choi WM, Lee D, Shim JH, et al. Risk of variceal bleeding in patients receiving atezolizumab-bevacizumab treatment for hepatocellular carcinoma. Aliment Pharmacol Ther. 2025;61:1310\u20137. https:\/\/doi.org\/10.1111\/apt.18526.","journal-title":"Aliment Pharmacol Ther"},{"key":"1843_CR46","doi-asserted-by":"publisher","first-page":"101065","DOI":"10.1016\/j.jhepr.2024.101065","volume":"6","author":"N Ben Khaled","year":"2024","unstructured":"Ben Khaled N, M\u00f6ller M, Jochheim LS, Leyh C, Ehmer U, B\u00f6ttcher K, et al. Atezolizumab\/bevacizumab or lenvatinib in hepatocellular carcinoma: multicenter real-world study with focus on bleeding and thromboembolic events. JHEP Rep. 2024;6:101065. https:\/\/doi.org\/10.1016\/j.jhepr.2024.101065.","journal-title":"JHEP Rep"},{"key":"1843_CR47","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s12072-022-10303-0","volume":"16","author":"J Dana","year":"2022","unstructured":"Dana J, Venkatasamy A, Saviano A, Lupberger J, Hoshida Y, Vilgrain V, et al. Conventional and artificial intelligence-based imaging for biomarker discovery in chronic liver disease. Hepatol Int. 2022;16:509\u201322. https:\/\/doi.org\/10.1007\/s12072-022-10303-0.","journal-title":"Hepatol Int"},{"key":"1843_CR48","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1136\/gutjnl-2024-334133","volume":"74","author":"C Wang","year":"2025","unstructured":"Wang C, Felli E, Fallowfield JA, Dietrich CF, Rockey D, Hennig J, et al. Vasomics of the liver. Gut. 2025;74:1008\u201320. https:\/\/doi.org\/10.1136\/gutjnl-2024-334133.","journal-title":"Gut"},{"key":"1843_CR49","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1007\/s00330-025-12010-4","volume":"36","author":"A Yamamoto","year":"2026","unstructured":"Yamamoto A, Sato S, Ueda D, Walston SL, Kageyama K, Jogo A, et al. Deep-learning-based prediction of significant portal hypertension with single cross-sectional non-enhanced CT. Eur Radiol. 2026;36:1899\u2013908. https:\/\/doi.org\/10.1007\/s00330-025-12010-4.","journal-title":"Eur Radiol"},{"key":"1843_CR50","doi-asserted-by":"publisher","first-page":"e078378","DOI":"10.1136\/bmj-2023-078378","volume":"385","author":"GS Collins","year":"2024","unstructured":"Collins GS, Moons KGM, Dhiman P, Riley RD, Beam AL, Van Calster B, et al. TRIPOD\u2009+\u2009AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods. BMJ. 2024;385:e078378. https:\/\/doi.org\/10.1136\/bmj-2023-078378.","journal-title":"BMJ"},{"key":"1843_CR51","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1097\/HEP.0000000000001498","volume":"83","author":"BV John","year":"2026","unstructured":"John BV, Bastaich DR, Deng Y, Singal AG, Dahman B. Use of liver stiffness measurement for HCC risk stratification in metabolic dysfunction-associated steatotic liver disease. Hepatology. 2026;83:1456\u201368. https:\/\/doi.org\/10.1097\/HEP.0000000000001498.","journal-title":"Hepatology"},{"key":"1843_CR52","doi-asserted-by":"publisher","first-page":"101739","DOI":"10.1016\/j.jhepr.2026.101739","volume":"8","author":"J Embacher","year":"2026","unstructured":"Embacher J, Remih K, Schneider CV, Jachs M, Balcar L, Th\u00f6ne P, et al. Non-invasive tests to guide hepatocellular carcinoma surveillance. JHEP Rep. 2026;8:101739. https:\/\/doi.org\/10.1016\/j.jhepr.2026.101739.","journal-title":"JHEP Rep"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-026-01843-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-026-01843-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-026-01843-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:56:08Z","timestamp":1792104968000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-026-01843-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,15]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1843"],"URL":"https:\/\/doi.org\/10.1007\/s11912-026-01843-x","relation":{},"ISSN":["1534-6269"],"issn-type":[{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,15]]},"assertion":[{"value":"27 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"104"}}